ALNY
Price
$260.63
Change
-$6.20 (-2.32%)
Updated
Apr 3, 02:28 PM (EDT)
Capitalization
34.53B
28 days until earnings call
EXEL
Price
$36.65
Change
-$0.39 (-1.05%)
Updated
Apr 3, 02:37 PM (EDT)
Capitalization
10.37B
40 days until earnings call
Ad is loading...

ALNY vs EXEL

Header iconALNY vs EXEL Comparison
Open Charts ALNY vs EXELBanner chart's image
Alnylam Pharmaceuticals
Price$260.63
Change-$6.20 (-2.32%)
Volume$400
Capitalization34.53B
Exelixis
Price$36.65
Change-$0.39 (-1.05%)
Volume$888
Capitalization10.37B
ALNY vs EXEL Comparison Chart
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. EXEL commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and EXEL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ALNY: $266.83 vs. EXEL: $37.04)
Brand notoriety: ALNY: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 109% vs. EXEL: 70%
Market capitalization -- ALNY: $34.53B vs. EXEL: $10.37B
ALNY [@Biotechnology] is valued at $34.53B. EXEL’s [@Biotechnology] market capitalization is $10.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileEXEL’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • EXEL’s FA Score: 1 green, 4 red.
According to our system of comparison, EXEL is a better buy in the long-term than ALNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 5 TA indicator(s) are bullish while EXEL’s TA Score has 3 bullish TA indicator(s).

  • ALNY’s TA Score: 5 bullish, 5 bearish.
  • EXEL’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than EXEL.

Price Growth

ALNY (@Biotechnology) experienced а -0.88% price change this week, while EXEL (@Biotechnology) price change was +0.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.84%. For the same industry, the average monthly price growth was -9.88%, and the average quarterly price growth was -14.17%.

Reported Earning Dates

ALNY is expected to report earnings on May 01, 2025.

EXEL is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-7.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($34.5B) has a higher market cap than EXEL($10.4B). ALNY YTD gains are higher at: 13.395 vs. EXEL (11.231). EXEL has higher annual earnings (EBITDA): 719M vs. ALNY (-178.85M). ALNY has more cash in the bank: 2.7B vs. EXEL (1.11B). EXEL has less debt than ALNY: EXEL (191M) vs ALNY (1.3B). ALNY (2.25B) and EXEL (2.17B) have equivalent revenues.
ALNYEXELALNY / EXEL
Capitalization34.5B10.4B332%
EBITDA-178.85M719M-25%
Gain YTD13.39511.231119%
P/E RatioN/A21.05-
Revenue2.25B2.17B104%
Total Cash2.7B1.11B243%
Total Debt1.3B191M679%
FUNDAMENTALS RATINGS
ALNY vs EXEL: Fundamental Ratings
ALNY
EXEL
OUTLOOK RATING
1..100
2169
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
2222
SMR RATING
1..100
10040
PRICE GROWTH RATING
1..100
4241
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (76) in the Biotechnology industry is in the same range as ALNY (99). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's Profit vs Risk Rating (22) in the Biotechnology industry is in the same range as ALNY (22). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that EXEL’s stock grew somewhat faster than ALNY’s over the last 12 months.

EXEL's Price Growth Rating (41) in the Biotechnology industry is in the same range as ALNY (42). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

EXEL's P/E Growth Rating (90) in the Biotechnology industry is in the same range as ALNY (100). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYEXEL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
58%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
60%
Advances
ODDS (%)
Bullish Trend 11 days ago
75%
Bullish Trend 15 days ago
65%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 7 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
57%
View a ticker or compare two or three
Ad is loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPYG81.620.67
+0.83%
SPDR® Portfolio S&P 500 Growth ETF
KNCT101.550.53
+0.53%
Invesco Next Gen Connectivity ETF
JEMA38.530.04
+0.10%
JPMorgan ActiveBuilders EM Eq ETF
FLKR18.61-0.03
-0.16%
Franklin FTSE South Korea ETF
EDD4.74-0.02
-0.42%
Morgan Stanley Emerging Markets Domestic Debt Fund

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+4.33%
IONS - ALNY
50%
Loosely correlated
+5.32%
ATRA - ALNY
44%
Loosely correlated
+2.00%
SGMO - ALNY
42%
Loosely correlated
+14.58%
ARGX - ALNY
40%
Loosely correlated
+2.91%
AMLX - ALNY
40%
Loosely correlated
+13.17%
More

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.79%
SRPT - EXEL
36%
Loosely correlated
+0.90%
ALNY - EXEL
34%
Loosely correlated
+4.33%
TECH - EXEL
33%
Poorly correlated
+1.80%
MRSN - EXEL
32%
Poorly correlated
+1.68%
ORMP - EXEL
32%
Poorly correlated
+3.29%
More